Kura Oncology to partner with Kyowa Kirin for blood cancer therapy (updated)
20/11/2024 22:36
(Adds details on the drug and the partnership in paragraphs 2
to 6)
Nov 20 (Reuters) - Kura Oncology KURA.O said on
Wednesday it will collaborate with Japan's Kyowa Kirin 4151.T
to develop and commercialize the blood cancer therapy
ziftomenib.
Kura will lead the development of the drug, which is
currently being evaluated for the treatment of acute myeloid
leukemia, a blood and bone marrow cancer that affects about
20,000 people in the United States every year.
The companies will jointly undertake commercialization
activities and will equally share potential profits and losses,
Kura said.
Kyowa Kirin would develop and commercialize the drug
outside the United States.
Kura said it will receive an upfront payment of $330
million and up to $1.2 billion in total milestone payments as
part of the deal.
Ziftomenib is currently in early-stage development. The
oral drug is also being tested for other blood cancers.
(Reporting by Christy Santhosh in Bengaluru; Editing by
Mohammed Safi Shamsi)
((Christy.Santhosh@thomsonreuters.com;))